- Home
- BB vs KNSA Comparison
BB vs KNSA Comparison
Compare BB & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BB | KNSA |
|---|---|---|
| Founded | 1984 | 2015 |
| Country | Canada | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.9B |
| IPO Year | 1999 | 2018 |
Fundamental Metrics
Financial Performance| Metric | BB | KNSA |
|---|---|---|
| Price | $7.64 | $79.20 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $4.85 | ★ $60.86 |
| AVG Volume (30 Days) | ★ 9.3M | 394.7K |
| Earning Date | 04-09-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 169.23 | ★ 225.00 |
| EPS | 0.09 | ★ 0.27 |
| Revenue | $549,100,000.00 | ★ $677,564,000.00 |
| Revenue This Year | $12.21 | $37.48 |
| Revenue Next Year | $8.95 | $17.87 |
| P/E Ratio | ★ $87.00 | $293.63 |
| Revenue Growth | 2.65 | ★ 60.09 |
| 52 Week Low | $3.12 | $35.11 |
| 52 Week High | $13.59 | $82.94 |
Technical Indicators
Market Signals| Indicator | BB | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 38.38 | 59.99 |
| Support Level | $7.67 | $44.95 |
| Resistance Level | $9.34 | $82.25 |
| Average True Range (ATR) | 0.35 | 2.14 |
| MACD | -0.02 | -0.59 |
| Stochastic Oscillator | 5.56 | 67.35 |
Price Performance
Historical ComparisonAbout BB BlackBerry Limited
BlackBerry, once known for being the world's largest smartphone manufacturer, is now exclusively a software provider with a stated goal of end-to-end secure communications for enterprises. The firm provides endpoint management and other secure communications software to enterprises, specializing in regulated industries like government and financial institutions. BlackBerry also has a sizable embedded software business primarily serving the automotive market, with some exposure to the industrial market.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.